AbbVie
Trade AbbVie 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About ABBV
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions.
ABBV Key Statistics
Stock Snapshot
AbbVie(ABBV) stock is priced at $232.22, giving the company a market capitalization of 421.56B. It carries a P/E multiple of 97.13 and pays a dividend yield of 2.9%.
As of 2026-02-14, AbbVie(ABBV) stock has fluctuated between $227.07 and $234.74. The current price stands at $232.22, placing the stock +2.3% above today's low and -1.1% off the high.
The AbbVie(ABBV)'s current trading volume is 8.25M, compared to an average daily volume of 8.36M.
During the past year, AbbVie(ABBV) stock moved between $164.39 at its lowest and $244.81 at its peak.
During the past year, AbbVie(ABBV) stock moved between $164.39 at its lowest and $244.81 at its peak.
ABBV News
Growth, value, or both? Healthcare industry stocks are traditionally good hedges against technology and other growth stocks, because they tend to perform well...
If you are wondering whether AbbVie is still reasonably priced after its strong run, this article walks through what the current share price could be implying a...
Abbvie (ABBV) announced an update on their ongoing clinical study. AbbVie (ABBV) is running a Phase 2 study called “A Phase 2 Double-Blind, Placebo-Controlled,...
Analyst ratings
64%
of 33 ratingsMore ABBV News
AbbVie has sued the Department of Health and Human Services (HHS), challenging the agency’s decision to select its blockbuster anti-wrinkle therapy Botox for th...
Abbvie (ABBV) announced an update on their ongoing clinical study. AbbVie (ABBV) has completed a post-marketing study in Korea called “Post-marketing Surveilla...
Abbvie (ABBV) announced an update on their ongoing clinical study. The AbbVie (ABBV) study, titled “A Randomized, Double-Blind, Placebo-Controlled Proof of Con...
Advertisement Why AbbVie’s latest earnings and pipeline moves matter now AbbVie (ABBV) has just paired a strong fourth quarter with two important developments...
Abbvie (ABBV) announced an update on their ongoing clinical study. The AbbVie (ABBV) PHASES study, officially titled “Prodrome in tHe reAl World: aSsESsing Ubr...
In early February 2026, AbbVie reported past fourth-quarter 2025 results showing sales rising to US$16,618 million and net income improving to US$1,816 million,...
AbbVie has submitted regulatory applications to the FDA and EMA for Rinvoq as a potential systemic treatment for non segmental vitiligo. The filings target a c...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.